Article
PRMT5 is a therapeutic target in choroidal neovascularization
2022-03-30
Abstract excerpt
Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients’ non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel therapeutic target for nvAMD. PRMT5 is a well-known epigenetic e...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 772c31e0-9692-5fb7-9642-2732c2f9e30b
- DOI
- 10.1101/2022.03.30.486275
